Global Assets Advisory LLC Purchases Shares of 1,652 Danaher Corporation (NYSE:DHR)

Global Assets Advisory LLC purchased a new stake in Danaher Corporation (NYSE:DHR - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,652 shares of the conglomerate's stock, valued at approximately $312,000.

Several other hedge funds also recently added to or reduced their stakes in the business. Financial Enhancement Group LLC boosted its holdings in Danaher by 5.8% in the first quarter. Financial Enhancement Group LLC now owns 11,012 shares of the conglomerate's stock valued at $2,115,000 after purchasing an additional 604 shares during the last quarter. International Assets Investment Management LLC boosted its holdings in Danaher by 39.5% in the first quarter. International Assets Investment Management LLC now owns 2,191 shares of the conglomerate's stock valued at $449,000 after purchasing an additional 620 shares during the last quarter. Cornerstone Wealth Group LLC boosted its holdings in Danaher by 8.1% in the first quarter. Cornerstone Wealth Group LLC now owns 1,274 shares of the conglomerate's stock valued at $261,000 after purchasing an additional 95 shares during the last quarter. Community Financial Services Group LLC boosted its holdings in Danaher by 4.0% in the first quarter. Community Financial Services Group LLC now owns 18,411 shares of the conglomerate's stock valued at $3,774,000 after purchasing an additional 713 shares during the last quarter. Finally, Sava Infond d.o.o. boosted its holdings in Danaher by 27.8% in the first quarter. Sava Infond d.o.o. now owns 4,140 shares of the conglomerate's stock valued at $849,000 after purchasing an additional 900 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DHR has been the topic of several recent analyst reports. Stifel Nicolaus raised shares of Danaher from a "hold" rating to a "buy" rating and set a $260.00 target price on the stock in a research note on Friday, March 14th. JPMorgan Chase & Co. lowered their target price on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 22nd. Wells Fargo & Company lowered their target price on shares of Danaher from $240.00 to $210.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 23rd. TD Cowen increased their target price on shares of Danaher from $240.00 to $248.00 and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Finally, UBS Group lowered their target price on shares of Danaher from $275.00 to $240.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $248.61.

Danaher Stock Up 1.7%

DHR opened at $200.85 on Thursday. The company has a market cap of $143.74 billion, a PE ratio of 39.00, a price-to-earnings-growth ratio of 2.77 and a beta of 0.77. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $281.70. The company has a 50-day moving average price of $194.31 and a 200 day moving average price of $209.00.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.26. The company had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a net margin of 15.81% and a return on equity of 10.80%. Sell-side analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.64%. Danaher's payout ratio is 24.85%.

Insider Buying and Selling at Danaher

In other news, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the sale, the chairman now owns 3,105,808 shares in the company, valued at $611,036,665.92. This trade represents a 28.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president now directly owns 15,179 shares in the company, valued at approximately $3,005,442. The trade was a 51.01% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is owned by insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.